cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-968Research ArticleАРТЕРИАЛЬНАЯ ГИПЕРТОНИЯARTERIAL HYPERTENSIONОценка эффективности, безопасности комбинированного применения периндоприла и индапамида в низких дозах у больных артериальной гипертонией в сочетании с метаболическим синдромомEfficacy, safety of combined perindopril and indapamide low-dose therapy in patients with arterial hypertension and metabolic syndromeАндрееваО. Н.AndreevaO. N.КорочкинИ. М.KorochkinI. M.РечноваН. П.RechnovaN. P.ПивоваровВ. Ю.PibovarovV. Yu.Российский государственный медицинский университетRussian State Medical UniversityКлиническая больница № 13, МоскваClinical Hospital No. 13, Moscow20052006200543, ч.I4652Copyright © Андреева О.Н., Корочкин И.М., Речнова Н.П., Пивоваров В.Ю., 20052005Андреева О.Н., Корочкин И.М., Речнова Н.П., Пивоваров В.Ю.Andreeva O.N., Korochkin I.M., Rechnova N.P., Pibovarov V.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/968

Цель. Изучить клинические, гемодинамические и метаболические эффекты 12-недельного применения препарата «Нолипрел®» (комбинация периндоприла 2 мг с индапамидом 0,625 мг) у больных артериальной гипертонией (АГ) в сочетании с метаболическим синдромом (МС). Материал и методы. В исследование включены 25 больных АГ в сочетании с МС. Исходно и через 12 недель терапии Нолипрелом® и Нолипрелом®-форте проводили суточное мониторирование артериального давления, оценивали показатели метаболизма и системы гемостаза. Результаты. Терапия Нолипрелом® и Нолипрелом®-форте в течение 12 недель привела к снижению АД в течение суток, индекса нагрузки давлением в дневное и ночное время, и нормализации двухфазного профиля АД. После лечения Нолипрелом® и Нолипрелом®-форте не были выявлены достоверные изменения в содержании липидов, глюкозы, инсулина в плазме крови. Повышенные показатели агрегации тромбоцитов достоверно улучшились на фоне терапии. Заключение. Полученные результаты продемонстрировали хороший антигипертензивный эффект препаратов в течение суток, метаболическую нейтральность.

Aim. To study clinical, hemodynamic, and metabolic effects of 12-week therapy with Noliprel® (perindopril 2 mg plus indapamide 0.625 mg) in patients with arterial hypertension (AH) and metabolic syndrome (MS). Material and methods. Twenty-five patients with AH and MS were enrolled in the study. At baseline, as well as after 12 weeks of Noliprel® and Noliprel Forte® therapy, 24-hour blood pressure monitoring (BPM), metabolic and hemostatic parameters’ assessments were performed. Results. Twelve-week therapy with Noliprel® and Noliprel Forte® resulted in decrease of circadian BP, day- and night-time pressure load indices, and BP bi-phase profile normalization. Treatment with Noliprel® and Noliprel Forte® did not significantly influence plasma levels of lipids, glucose, or insulin. Initially increased platelet aggregation substantially improved during the treatment. Conclusion. The results obtained demonstrate good antihypertensive effects during the whole day, and metabolic neutrality for both medications.

метаболический синдромнизкодозовая комбинированная терапияартериальная гипертонияагрегация тромбоцитовметаболическая нейтральностьmetabolic syndromecombined low-dose therapyarterial hypertensionplatelet aggregationmetabolic neutralityReferencesRitz E, Hasslacher C, Mann J, Guo Ji-Jhen. Hypertension and vascular disease as complications of diabetes. J Hypertens 1997; 7: 233-40.Ritz E, Hasslacher C, Mann J, Guo Ji-Jhen. Hypertension and vascular disease as complications of diabetes. J Hypertens 1997; 7: 233-40.Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37; 1595-607.Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37; 1595-607.Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-20.Kaplan NM. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-20.Henefeld M, Leonhardt W. Das metabolische Syndrome. Deutsch Ges Wes 1980; 36: 545-51.Henefeld M, Leonhardt W. Das metabolische Syndrome. Deutsch Ges Wes 1980; 36: 545-51.Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfounded randomized drug trials in an epidemiologic context. Lancet 1990: 335: 827-38.Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke and coronary heart disease. Part II: Effects of short term-reductions of blood pressure – an overview of the unconfounded randomized drug trials in an epidemiologic context. Lancet 1990: 335: 827-38.Metabolic aspects of Hypertensions. Ed. Norman M. Kaplan. London (UK): Science Press 1994.Metabolic aspects of Hypertensions. Ed. Norman M. Kaplan. London (UK): Science Press 1994.Taddeei S, Virdis A, Chiadoni L, Salvetti A. The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21: 22-9.Taddeei S, Virdis A, Chiadoni L, Salvetti A. The pivotal role of endothelium in hypertension. Medicographia 1999; Issue 59; 21: 22-9.Schiffrin EL, Hayoz D. Angiotensin II Receptor antagonists. Eds. M. Epstein, H.R.Brunner. Philadelphia: Hanley Belfus INC 2001; 279-89.Schiffrin EL, Hayoz D. Angiotensin II Receptor antagonists. Eds. M. Epstein, H.R.Brunner. Philadelphia: Hanley Belfus INC 2001; 279-89.Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens 1999; 21: 875-84.Chalmers J. The importance of drug combinations for effective control of hypertension. Clin Exp Hypertens 1999; 21: 875-84.Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157: 2413-46.Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 1997; 157: 2413-46.WHO-ISH Guidelines Sub-Committee. 1999 WHO-ISH Guidelines for the management of mild hypertension. J Hypertens 1999; 17: 151-83.WHO-ISH Guidelines Sub-Committee. 1999 WHO-ISH Guidelines for the management of mild hypertension. J Hypertens 1999; 17: 151-83.Chalmers J, Castaigne A, Morgan T, Chatang C. Longterm efficacy of a new, fixed, very-low-dose angiotensinconverting enzyme-inhibitor/diuretic combination as firstline therapy in elderly hypertensive patients. J Hypertens 2000; 18: 327-37.Chalmers J, Castaigne A, Morgan T, Chatang C. Longterm efficacy of a new, fixed, very-low-dose angiotensinconverting enzyme-inhibitor/diuretic combination as firstline therapy in elderly hypertensive patients. J Hypertens 2000; 18: 327-37.Determination of the optimal oral dose of perindopril (2,4 or 8 mg) in combination with indapamide (0.625, 1.25 or 2.5 mg) for 8 weeks in patients with mild-to-moderate essential hypertensions. Randomized double-blind, parallel-group, placeb-controlled stady. Expert report. May 1996.Determination of the optimal oral dose of perindopril (2,4 or 8 mg) in combination with indapamide (0.625, 1.25 or 2.5 mg) for 8 weeks in patients with mild-to-moderate essential hypertensions. Randomized double-blind, parallel-group, placeb-controlled stady. Expert report. May 1996.Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide. J Hypertsns 2000; 18: 317-25.Myers MG, Asmar R, Leenen FHH, Safar M. Fixed low-dose combination therapy in hypertension – a dose response study of perindopril and indapamide. J Hypertsns 2000; 18: 317-25.Castaigne A, Chalmers J, Morgan T, et al. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild-to moderate hypertension. Clin Exp Hypertens 1999; 21(7): 1097-110.Castaigne A, Chalmers J, Morgan T, et al. Efficacy and safety of an oral fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination: a randomized, double-blind, placebo-controlled study in elderly patients with mild-to moderate hypertension. Clin Exp Hypertens 1999; 21(7): 1097-110.Machnig T, Engals Henneke KH, et al. Ambulatory blood pressure monitoring: significance of blood pressure variability for progression of heart hypertrophy. Cardiology 1993; 82(3): 187-91.Machnig T, Engals Henneke KH, et al. Ambulatory blood pressure monitoring: significance of blood pressure variability for progression of heart hypertrophy. Cardiology 1993; 82(3): 187-91.Caro F. Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991; 73: 691-5.Caro F. Insulin resistance in obese and nonobese man. J Clin Endocrinol Metab 1991; 73: 691-5.National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Bethesda, Md: National Institutes of Health; 2001. NIH Publication 01-3670.National Institutes of Health. Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adults Treatment Panel III). Bethesda, Md: National Institutes of Health; 2001. NIH Publication 01-3670.

The authors declare that there are no conflicts of interest present.